Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Gains from Investment Securities (2020 - 2025)

Biofrontera has reported Gains from Investment Securities over the past 6 years, most recently at $442000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $442000.0 for Q4 2025, down 68.06% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (up 3460.0% YoY), and the annual figure for FY2025 was $719844.0, down 44.2%.
  • Gains from Investment Securities for Q4 2025 was $442000.0 at Biofrontera, up from $285000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for BFRIW hit a ceiling of $1.8 billion in Q3 2022 and a floor of -$5.4 million in Q2 2024.
  • Median Gains from Investment Securities over the past 5 years was $38500.0 (2021), compared with a mean of $92.7 million.
  • Peak annual rise in Gains from Investment Securities hit 262779.57% in 2022, while the deepest fall reached 268650.0% in 2022.
  • Biofrontera's Gains from Investment Securities stood at $47000.0 in 2021, then surged by 38044.68% to $17.9 million in 2022, then crashed by 88.76% to $2.0 million in 2023, then crashed by 31.35% to $1.4 million in 2024, then crashed by 68.06% to $442000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $442000.0 (Q4 2025), $285000.0 (Q3 2025), and -$153000.0 (Q2 2025) per Business Quant data.